Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
US6635648B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2001 |
| Grant date | Oct 21, 2003 |
| Priority date | — |
| Expiry date | Aug 16, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for preventing or inhibiting adverse cardiovascular effects associated with administration of a sympathetic nervous system antagonist in a subject, in which a subject in need thereof is administered a sympathetic nervous system antagonist and an endothelin antagonist. Methods for improving the efficacy of a sympathetic nervous system antagonist are also provided, comprising administering to a subject in need thereof a sympathetic nervous system antagonist together with an endothelin antagonist. Methods of treating prostate cancer or benign prostate hyperplasia (BPH) in a subject are also provided, in which a subject in need thereof is administered a sympathetic nervous system antagonist and an endothelin antagonist. The sympathetic nervous system antagonist may be an alpha-adrenoceptor antagonist, a ganglionic blocking agent or another inhibitor of the actions of the sympathetic nervous system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.